Brolucizumab for treating wet age-related macular degeneration (AMD) in adults – final appraisal determination

In this DRAFT guidance, brolucizumab is recommended for wet AMD if best-corrected visual acuity is 6/12 to 6/96, there is no permanent structural damage, lesion size is at least 12 disc areas & there is recent disease progression (e.g. blood vessel growth).

Source:

National Institute for Health and Care Excellence